[Therapeutic experience of S-1 plus other drug combination therapy for synchronia multiple liver metastases of gastric cancer].
A treatment of multiple liver metastases of gastric cancer is very hard and its prognosis is extremely poor. At this time, we reviewed an efficacy of the therapeutic experience case with a new anticancer agent. The treatment was performed on nine cases of synchronia multiple liver metastases of gastric cancer since the new anticancer agent was introduced to the treatment. All of the 9 gastric cancer cases were diagnosed as being resectable other than ones with metastases to the liver, or a primary tumor resection was performed on the cases. The 1st line chemotherapy regimen was a combination of S-1+CDDP intra-arterial injection. The 2nd line chemotherapy regimen was S-1+CPT-11 intra-arterial injection. Furthermore, the 3rd line chemotherapy regimen was an administration of paclitaxel. There were no adverse events, such as hematotoxicity and non-hematotoxicity, that were greater than grade 3 during the duration of chemotherapy. Hence, we could continue the treatment regimen on all of the cases. The tumor responses for all of the cases were judged to be stable disease (SD). The best overall responses for all of the cases were judged to be progressive disease (PD). A median survival time (MST) of the treatment was 16 months, and that was significantly improved from 5.5 months, the regimen without a new anticancer agent (p=0.002). An ambulatory treatment was capable with the QOL in all of the cases. In conclusion, the tumor response did not show on the imaging, but it could be evaluable when there was an efficacy in the treatment that would support a daily life of patient.
Yano
Shojiro
S
Dept. of Surgery, Kurume University School of Medicine, Japan.
Kizaki
Junya
J
Imaizumi
Takuya
T
Koga
Atsuhiko
A
Miyagi
Motoshi
M
Shirouzu
Kazuo
K
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid